Medtronic PLC $MDT Shares Acquired by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. raised its stake in Medtronic PLC (NYSE:MDT) by 6.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 140,059 shares of the medical technology company’s stock after purchasing an additional 8,034 shares during the period. Brown Brothers Harriman & Co.’s holdings in Medtronic were worth $13,339,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Cadence Bank increased its stake in Medtronic by 0.7% in the third quarter. Cadence Bank now owns 77,532 shares of the medical technology company’s stock valued at $7,384,000 after purchasing an additional 530 shares during the last quarter. Game Creek Capital LP grew its holdings in shares of Medtronic by 231.1% during the third quarter. Game Creek Capital LP now owns 61,250 shares of the medical technology company’s stock worth $5,833,000 after buying an additional 42,750 shares during the last quarter. Pathstone Holdings LLC increased its holdings in shares of Medtronic by 6.2% in the third quarter. Pathstone Holdings LLC now owns 132,363 shares of the medical technology company’s stock valued at $12,619,000 after purchasing an additional 7,681 shares during the period. GeoWealth Management LLC increased its stake in Medtronic by 60.4% in the 3rd quarter. GeoWealth Management LLC now owns 51,948 shares of the medical technology company’s stock valued at $4,948,000 after buying an additional 19,567 shares during the period. Finally, Resurgent Financial Advisors LLC increased its stake in shares of Medtronic by 4.2% during the third quarter. Resurgent Financial Advisors LLC now owns 5,494 shares of the medical technology company’s stock worth $523,000 after acquiring an additional 220 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of MDT stock opened at $87.05 on Friday. The stock has a fifty day moving average price of $97.96 and a 200 day moving average price of $96.84. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The stock has a market cap of $111.77 billion, a PE ratio of 24.25, a P/E/G ratio of 2.24 and a beta of 0.71. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the previous year, the company posted $1.38 EPS. The business’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio is 79.11%.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.26% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Morgan Stanley lifted their price objective on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. CICC Research initiated coverage on Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating on the stock. TD Cowen reiterated a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Sanford C. Bernstein raised their target price on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $110.74.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).